^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib

Published date:
11/18/2020
Excerpt:
This was a cohort study on genetic alterations in patients with BRAFV600E mutant advanced colorectal cancer treated with inhibitors of the MAPK pathway....Genetic alterations in EGFR and in PIK3CA are associated with non-response....Genetic alterations in the PI3K and upstream receptor tyrosine kinases were mostly associated with intrinsic and acquired resistance.
DOI:
10.1038/s41416-020-01147-2